Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

• Published in: Blood Vol. 135; no. 25; pp. 2224 - 2234
• Main Authors: Schöder, Heiko, Polley, Mei-Yin C., Knopp, Michael V., Hall, Nathan, Kostakoglu, Lale, Zhang, Jun, Higley, Howard R., Kelloff, Gary, Liu, Heshan, Zelenetz, Andrew D., Cheson, Bruce D., Wagner-Johnston, Nina, Kahl, Brad S., Friedberg, Jonathan W., Hsi, Eric D., Leonard, John P., Schwartz, Lawrence H., Wilson, Wyndham H., Bartlett, Nancy L.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 18.06.2020; American Society of Hematology
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Clinical Trials and Observations; Cyclophosphamide - administration & dosage; Etoposide - administration & dosage; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse - diagnostic imaging; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - mortality; Male; Middle Aged; Positron-Emission Tomography; Prednisone - administration & dosage; Prognosis; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Radiopharmaceuticals; Rituximab - administration & dosage; Vincristine - administration & dosage; Young Adult
• ISSN: 0006-4971; 1528-0020; 1528-0020
• DOI: 10.1182/blood.2019003277

As part of a randomized, prospective clinical trial in large cell lymphoma, we conducted serial fluorodeoxyglucose positron emission tomography (FDG-PET) at baseline, after 2 cycles of chemotherapy (interim PET [i-PET]), and at end of treatment (EoT) to identify biomarkers of response that are predi...